Other ASH Meetings

Other ASH Meetings

Highlights and interviews from the American Society of Hematology’s meetings

Inotuzumab Ozogamicin Plus Low-Intensity Chemotherapy Is Safe, Effective in Older Patients With ALL

In February 2017, the U.S. Food and Drug Administration granted inotuzumab ozogamicin priority review for the treatment of adult patients with relapsed/refractory B-cell precursor...

Harnessing the Power of Gene Editing

For years, scientists have been manipulating genes in animal and human cells to gain a better understanding of how genomes work, with an eye...

ASH Sickle Cell Disease Summit: A Call to Action

In mid-April, more than 60 experts in sickle cell disease (SCD), including clinicians and researchers, federal agency partners, representatives from industry, and other members...
Advertisement

Current Issue

November 2017, Volume 3, Issue 13

This issue features a behind-the-scenes look at the ASH annual meeting, bringing newly approved gene therapies to patients, and more.